BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 20598466)

  • 1. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.
    Uriel N; Pak SW; Jorde UP; Jude B; Susen S; Vincentelli A; Ennezat PV; Cappleman S; Naka Y; Mancini D
    J Am Coll Cardiol; 2010 Oct; 56(15):1207-13. PubMed ID: 20598466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.
    Goda M; Jacobs S; Rega F; Peerlinck K; Jacquemin M; Droogne W; Vanhaecke J; Van Cleemput J; Van den Bossche K; Meyns B
    J Heart Lung Transplant; 2013 May; 32(5):539-45. PubMed ID: 23570742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
    Meyer AL; Malehsa D; Bara C; Budde U; Slaughter MS; Haverich A; Strueber M
    Circ Heart Fail; 2010 Nov; 3(6):675-81. PubMed ID: 20739614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).
    Starling RC; Naka Y; Boyle AJ; Gonzalez-Stawinski G; John R; Jorde U; Russell SD; Conte JV; Aaronson KD; McGee EC; Cotts WG; DeNofrio D; Pham DT; Farrar DJ; Pagani FD
    J Am Coll Cardiol; 2011 May; 57(19):1890-8. PubMed ID: 21545946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device.
    Malehsa D; Meyer AL; Bara C; StrĂ¼ber M
    Eur J Cardiothorac Surg; 2009 Jun; 35(6):1091-3. PubMed ID: 19303790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
    John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
    Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
    JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients.
    Crow S; Chen D; Milano C; Thomas W; Joyce L; Piacentino V; Sharma R; Wu J; Arepally G; Bowles D; Rogers J; Villamizar-Ortiz N
    Ann Thorac Surg; 2010 Oct; 90(4):1263-9; discussion 1269. PubMed ID: 20868825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II).
    Klovaite J; Gustafsson F; Mortensen SA; Sander K; Nielsen LB
    J Am Coll Cardiol; 2009 Jun; 53(23):2162-7. PubMed ID: 19497443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices.
    Birschmann I; Dittrich M; Eller T; Wiegmann B; Reininger AJ; Budde U; StrĂ¼ber M
    J Heart Lung Transplant; 2014 Jan; 33(1):80-7. PubMed ID: 24418734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes.
    Kormos RL; Teuteberg JJ; Pagani FD; Russell SD; John R; Miller LW; Massey T; Milano CA; Moazami N; Sundareswaran KS; Farrar DJ;
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1316-24. PubMed ID: 20132950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation.
    Boyle AJ; Russell SD; Teuteberg JJ; Slaughter MS; Moazami N; Pagani FD; Frazier OH; Heatley G; Farrar DJ; John R
    J Heart Lung Transplant; 2009 Sep; 28(9):881-7. PubMed ID: 19716039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
    Slaughter MS; Naka Y; John R; Boyle A; Conte JV; Russell SD; Aaronson KD; Sundareswaran KS; Farrar DJ; Pagani FD
    J Heart Lung Transplant; 2010 Jun; 29(6):616-24. PubMed ID: 20400335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices.
    Patel ND; Weiss ES; Schaffer J; Ullrich SL; Rivard DC; Shah AS; Russell SD; Conte JV
    Ann Thorac Surg; 2008 Sep; 86(3):832-40; discussion 832-40. PubMed ID: 18721570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe upper gastrointestinal bleeding in Heartmate II induced by acquired von Willebrand deficiency: anticoagulation management.
    Sponga S; Nalli C; Casonato A; Charbonneau E
    Ann Thorac Surg; 2012 Aug; 94(2):e41-3. PubMed ID: 22579885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients.
    Crow S; Milano C; Joyce L; Chen D; Arepally G; Bowles D; Thomas W; Ortiz NV
    ASAIO J; 2010; 56(5):441-5. PubMed ID: 20613494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients.
    Joyce D; Crow S; Li Z; Joyce L; Milano C; Rogers J; Villamizar-Ortiz N; Chen D
    J Heart Lung Transplant; 2012 Jul; 31(7):750-6. PubMed ID: 22538169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.